老龄化黄斑部病变（AMD）市场规模、份额、成长分析：产品类型、分子类型、核准类型、AMD类型、最终用户和地区 - 产业预测，2026-2033年

预计到 2024 年，老龄化黄斑部病变(AMD) 市场规模将达到 112.9 亿美元，到 2025 年将增长至 125.1 亿美元，到 2033 年将增长至 284.2 亿美元，在预测期（2026-2033 年）内，复合年增长率为 10.8%。

老龄化黄斑部病变（AMD）是一种进行性眼科疾病，主要影响老年人，涉及视网膜中央区域，逐渐导致视力丧失。此病主要分为干性AMD和湿性AMD两种类型，其中干性AMD较常见。虽然改变生活方式和补充维生素可以有效控制干性AMD，但湿性AMD需要更具侵入性的治疗，通常是注射抗VEGF药物来抑制异常血管增生。由于此病患病率不断上升以及人口老化导致人们对药物的依赖性日益增强，全球AMD治疗市场正在不断扩大。因此，寻求AMD治疗的患者人数不断增长，预示着旨在改善患者生活品质的创新治疗方法和预防措施的市场需求将持续增长。

老龄化黄斑部病变（AMD）市场成长要素

全球老龄化黄斑部病变（AMD）市场的成长主要受老年人口不断增长的推动，老年人更容易患上这种疾病。随着预期寿命的延长，越来越多的人面临与AMD相关的风险因素。这一趋势导致人们对有效治疗方法的需求不断增长，这些方案旨在控制病情并预防视力丧失。由于医疗服务提供者和患者都希望应对这种与老龄化相关的视力障碍带来的影响，因此迫切需要找到解决AMD挑战的方案，最终推动了市场的创新和扩张。

老龄化黄斑部病变市场的阻碍因素

由于某些地区筛检和诊断流程不完善，老龄化黄斑部病变）市场面临严峻挑战，不仅对患者的健康结果产生负面影响，也导致治疗延误。此外，人们对现有诊断工具的认知度较低，也阻碍了市场扩张，导致患者延迟接受治疗。这种延误不仅限制了现有疗法的潜在疗效，也加重了疾病的整体负担。如果无法改善及时筛检的可近性，并加深对诊断方案的了解，市场将无法充分发挥其潜力，也难以为AMD患者提供最佳的治疗方案。

老龄化黄斑部病变（AMD）市场趋势

老龄化黄斑部病变(AMD) 市场已显着转向长效治疗方法，尤其是长效抗 VEGF 疗法。这一趋势旨在透过减少疾病管理所需的注射次数，提高患者的依从性。这些创新最大限度地减轻了治疗负担，改善了患者体验和治疗效果，并推动了 AMD 市场的整体成长。这些进步不仅解决了传统治疗方法面临的挑战，也预示着治疗方向将向更有效率、更人性化的治疗方法转变，最终将塑造 AMD 治疗的未来。

目录

介绍

• 调查目标
• 定义
• 市场覆盖范围

调查方法

• 资讯收集
• 二手和一手资料资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

前景
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 抑制因素
  • 任务
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 技术分析
• 定价分析
• 价值链分析
• 供应链分析
• 专利分析
• 客户和购买标准分析
• 案例研究分析

按产品分類的老龄化黄斑部病变治疗市场

• Ailea 和 Ailea HD
• Lucentis
• 瓦维兹莫
• 奇福布雷
• 其他产品

按分子分類的老龄化黄斑部病变药物市场

• 阿黄曲普
• 法瑞西单抗
• 雷珠单抗
• 培塞他可普兰
• 其他分子

按核准类型分類的老龄化黄斑部病变治疗市场

• 生物製药
• 生物相似药

按AMD类型分類的老龄化黄斑部病变治疗市场

• 湿性AMD
• 干性酸性矿山排水

按最终用户分類的老龄化黄斑部病变治疗市场

• 医院
• 长期照护机构
• 专业医疗中心
• 其他的

按地区分類的老龄化黄斑部病变治疗药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲（MEA）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争格局

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市占率（2025 年）

主要企业简介

• Biogen（US）
• Formycon AG（Germany）
• Coherus Biosciences（US）
• Biocon（India）
• Outlook Therapeutics, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Intas Pharmaceuticals Ltd.（India）
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.（China）
• Ocular Therapeutix, Inc.（US）
• Opthea Limited（Australia）
• Kodiak Sciences Inc.（US）
• Bio-Thera（China）
• Amgen Inc.（US）
• Alvotech（Iceland）
• Stealth Biotherapeutics Inc.（US）
• Alteogen Inc.（South Korea）
• Ocumension Therapeutics（China）
• Innovent（China）
• Regeneron Pharmaceuticals, Inc.（US）
• Shanghai Henlius Biotech, Inc.（China）

Age-related Macular Degeneration Market size was valued at USD 11.29 Billion in 2024 and is poised to grow from USD 12.51 Billion in 2025 to USD 28.42 Billion by 2033, growing at a CAGR of 10.8% during the forecast period (2026-2033).

Age-related macular degeneration (AMD) is a progressive eye condition affecting the central retina, leading to gradual vision loss, primarily in older adults. The condition is classified into two major types: dry and wet AMD, with dry being the more prevalent. While lifestyle modifications and vitamin supplements may help manage dry AMD, wet AMD requires more invasive treatments, typically involving anti-VEGF injections to inhibit the growth of abnormal blood vessels. The global AMD market is expanding, driven by the increasing prevalence of this condition among the aging population and their reliance on medication. Consequently, the rise in patients seeking treatment for AMD suggests a growing market for therapeutic innovations and preventative measures aimed at improving the quality of life for those affected.

Top-down and bottom-up approaches were used to estimate and validate the size of the Age-related Macular Degeneration market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Age-related Macular Degeneration Market Segments Analysis

Global Age-related Macular Degeneration Market is segmented by Product, Molecule, Approval Type, Type of AMD, End User, and region. Based on Product, the market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Other Products. Based on Molecule, the market is segmented into Aflibercept, Faricimab, Ranibizumab, Pegcetacoplan, and Other Molecules. Based on Approval Type, the market is segmented into Biologics, and Biosimilars. Based on Type of AMD, the market is segmented into Wet AMD, and Dry AMD. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Age-related Macular Degeneration Market

The growth of the global age-related macular degeneration (AMD) market is significantly influenced by the rising population of older adults who are more vulnerable to this condition. As life expectancy increases, more individuals face heightened exposure to the risk factors associated with AMD. This trend has resulted in an increased demand for effective therapies and treatments aimed at managing the disease and preventing vision loss. The urgency for solutions to address the challenges posed by AMD ultimately drives innovation and expansion within the market, as both healthcare providers and patients seek to confront the impacts of this age-related vision impairment.

Restraints in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration market faces significant challenges due to inadequate screening and diagnostic processes in certain regions, which adversely affect health outcomes and contribute to treatment delays. Furthermore, a lack of awareness regarding available diagnostic tools hampers market expansion, leading to individuals receiving late interventions. This delay not only limits the potential effectiveness of existing therapies but also exacerbates the overall burden of the disease. Without improved access to timely screenings and a greater understanding of diagnostic options, the market struggles to realize its full potential and provide optimal patient care for those affected by AMD.

Market Trends of the Age-related Macular Degeneration Market

The Age-related Macular Degeneration (AMD) market is witnessing a notable shift towards long-acting therapies, particularly extended-duration anti-VEGF treatments. This trend addresses a critical need for improved patient compliance by reducing the frequency of injections required to manage the condition. By minimizing treatment burdens, these innovations enhance patient experience and outcomes, driving the overall growth of the AMD market. Such advancements not only respond to the challenges faced by previous therapies but also signify a broader movement toward more efficient and patient-friendly treatment modalities, ultimately shaping the future landscape of AMD management.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis
• Case Study Analysis

Age-Related Macular Degeneration Drugs Market by Product

• Market Overview
• Eylea & Eylea HD
• Lucentis
• Vabysmo
• Syfovre
• Other Products

Age-Related Macular Degeneration Drugs Market by Molecule

• Market Overview
• Aflibercept
• Faricimab
• Ranibizumab
• Pegcetacoplan
• Other Molecules

Age-Related Macular Degeneration Drugs Market by Approval Type

• Market Overview
• Biologics
• Biosimilars

Age-Related Macular Degeneration Drugs Market by Type of AMD

• Market Overview
• Wet AMD
• Dry AMD

Age-Related Macular Degeneration Drugs Market by End User

• Market Overview
• Hospitals
• Long-Term Care Facilities
• Specialty Centers
• Others

Age-Related Macular Degeneration Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formycon AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus Biosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Kanghong Pharmaceutical Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Thera (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvotech (Iceland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stealth Biotherapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alteogen Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocumension Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Henlius Biotech, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments